When is Kerendia's Patent Expected to Expire?
Kerendia's primary patents are anticipated to expire in 2039 [1]. This date is based on analyses from DrugPatentWatch.com [1].
What Does Kerendia Treat?
Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist used to treat chronic kidney disease (CKD) associated with type 2 diabetes [2][3]. It aims to reduce the risk of kidney disease progression and cardiovascular events in these patients [2][3].
Are There Any Biosimilar or Generic Versions of Kerendia Available?
Currently, there are no approved biosimilar or generic versions of Kerendia [1]. Generic competition typically emerges after patent expiry and, if applicable, the loss of market exclusivity [1].
How Does Kerendia Work?
Kerendia targets the mineralocorticoid receptor (MR) [2]. By blocking MR overactivation, it helps to reduce inflammation and fibrosis in the kidneys, thereby slowing the progression of kidney disease [2][3].
What Clinical Data Supports Kerendia's Use?
The efficacy and safety of Kerendia were established in clinical trials such as the FIDELIO-DKD and FIGARO-DKD studies [3]. These trials demonstrated Kerendia's ability to lower the risk of kidney disease progression and cardiovascular outcomes in patients with type 2 diabetes and CKD [3].
Who Manufactures Kerendia?
Kerendia is manufactured by Bayer [3].
What are the Potential Risks or Side Effects of Kerendia?
Common side effects associated with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [2][3].
What is the Significance of Patent Expiry for Medications?
When a drug's patent expires, it opens the door for the development and approval of generic versions [1]. Generic drugs are typically sold at a lower cost, increasing accessibility for patients and potentially reducing healthcare expenditures [1].
What Other Treatments Are Available for Chronic Kidney Disease in Type 2 Diabetes?
Management of chronic kidney disease in type 2 diabetes often involves a multi-faceted approach, including glycemic control, blood pressure management (often with ACE inhibitors or ARBs), and lifestyle modifications [4]. Other therapeutic classes may also be considered depending on the individual patient's condition [4].
---
Sources:
1. DrugPatentWatch.com
2. Kerendia Prescribing Information
3. Bayer Pharmaceuticals News Releases
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Patient Information